RxPONDER
Clinical trial key findings will be presented at San Antonio Breast Cancer Symposium
December 7-10, 2021
RxPONDER practice-changing results now published in
The New England Journal of Medicine
Additional RxPONDER data to be presented at SABCS 20211:
Oral Presentation | Wednesday, 12/8/21 10:15 AM CT
Updated results from a phase 3 randomized clinical trial in participants with 1-3 positive lymph nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer with Recurrence Score® (RS) ≤ 25 randomized to endocrine therapy +/- chemotherapy: SWOG S1007 (RxPONDER)
GS2-07 | Kalinsky
JOIN US FOR A PRESENTATION ON:
The Evolving Role of the Oncotype DX® Test in Breast Cancer: TAILORx, RxPONDER, and Beyond
Speakers:
Christy Russell, MD
Vice President, US Medical Affairs
Precision Oncology
Exact Sciences
Rick Baehner, MD
Chief Medical Officer
Precision Oncology
Exact Sciences
Thursday, 12/9/21, 12:00pm – 1:00pm CT
Other Presentations of Interest
Poster Discussion | Thursday, 12/9/21 7:00 AM CT
Expanding Downstaging Criteria in AJCC Pathologic Prognostic Staging Using OncotypeDx Breast Recurrence Score® Assay in T1-2N0 Hormone-Receptor Positive Patients Enrolled in the TAILORx Trial
PD9-01 | Kanter
Poster Discussion | Friday, 12/10/21 7:00 AM CT
Assessment of estrogen receptor (ESR1) mRNA expression for prediction of extended aromatase inhibitor benefit in HR-positive breast cancer using NRG Oncology/NSABP B-42
PD-15-05 | Mamounas
Debate | Friday, 12/10/21 11:30 AM CT
RxPONDER: Was it all OFS?
Chair: Burstein Real world use of the Oncotype DX® test in the management of breast cancer. The North East England experience.
P1-08-28 | Gault
Validation of a 16-gene genomic signature to identify early-stage invasive breast cancer patients who may omit radiotherapy
P2-08-01 | Fyles
Using OncotypeDX Breast Recurrence Score (RS) assay to define the role of neoadjuvant endocrine therapy (NET) in early-stage hormone receptor positive (HR+) breast cancer (BC)
P2-15-02 | Taylor
The majority of postmenopausal HR+, HER2-, N1 patients can be spared chemotherapy when decisions are guided with the Oncotype DX® test
RxPONDER clinical trial key findings1
- The majority of N1 postmenopausal patients can now be spared chemotherapy based on Recurrence Score® results 0-25, regardless of clinical pathological parameters1
- N1 premenopausal patients with Recurrence Score results 0-25 have a modest benefit from chemotherapy1
- RxPONDER results add to findings of SWOG S-8814, the study that established the Oncotype DX® test as predictive of chemotherapy benefit in N1 postmenopausal patients1,2
RxPONDER clinical trial design
- RxPONDER, independently led by the SWOG Cancer Research Network, is one of the largest clinical trials for patients with HR+, HER2- early breast cancer and N1 disease
- The trial was designed to determine the effect of chemotherapy, if any, in patients who had a Recurrence Score® result 0-25
-
REFERENCES